KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Tax Assets Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Teva Pharmaceutical Industries (TEVA) Liabilities from Discontinued Operations (2017)

Teva Pharmaceutical Industries' Liabilities from Discontinued Operations history spans 1 years, with the latest figure at 38000000.0 for Q4 2017.

For the quarter ending Q4 2017, Liabilities from Discontinued Operations changed N/A year-over-year to 38000000.0, compared with a TTM value of 38000000.0 through Dec 2017, changed N/A, and an annual FY2017 reading of 38000000.0, changed N/A over the prior year.
Liabilities from Discontinued Operations for Q4 2017 was 38000000.0 at Teva Pharmaceutical Industries.
The five-year high for Liabilities from Discontinued Operations was 38000000.0 in Q4 2017, with the low at 38000000.0 in Q4 2017.